Conference Coverage
Trending on the Eye Care Network
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
3
Retina Society 2026: SOL-1 shows intravitreal axitinib hydrogel superior to aflibercept in wet AMD
4
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
5
Retina Society 2026: LUGANO secondary data show reduced treatment burden with vorolanib insert despite missed primary end point
Latest News
Sep 25, 2026 | Commentary
Beyond the phenotype: Aqueous humor sampling moves retinoblastoma toward personalized therapy
Geographic atrophy in practice: Three cases that defined the textbook
Sep 25, 2026
Aurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal edema secondary to corneal endothelial dysfunction
Sep 25, 2026
Retina Society 2026: Subretinal deposits in AMD may flag severe aortic stenosis that increases surgical risk
Sep 25, 2026
Retina Society 2026: How blood biomarkers may predict GA speed
Sep 24, 2026
Advertisement
Shorts
0:32
Reducing patient treatment burden: The latest on EYP-1901
8 hours ago
0:49
Closing the gap between retina innovation and patient care
a day ago
0:46
ESCRS 2026: Why aceclidine drops are a task-specific solution
2 days ago
1:09
ESCRS 2026: Fitting light therapy into the cataract surgery workflow
3 days ago
0:55
Stop ignoring your eyelids: the hidden risk of dry eyes
6 days ago
0:56
ESCRS 2026: Why retinal measurements can be wrong
7 days ago
0:39
ESCRS 2026: What makes a good candidate for aceclidine drops?
9 days ago
1:03
Intra-Operative OCT During Glaucoma Surgeries
11 days ago
0:50
Building a low-level light therapy workflow
12 days ago
1:08
AI's growing role in ophthalmology screening and outcomes analysis
13 days ago
Digital Edition
Ophthalmology Times
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Ophthalmology Times
Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.
Ophthalmology Times Europe
Waste, cost and carbon are converging to reshape how cataract centres choose instruments.
Ophthalmology Times Europe
Why AI-driven functional imaging could change how clinicians assess and treat retinal disease
Ophthalmology Times Europe
David E. I. Pyott, CBE, MD(Hon), MBA, MA, discusses expanding subspecialty training and internationally recognized credentials in underserved regions.
Modern Retina
How this gene-agnostic optogenetic approach could fill a critical gap for advanced inherited retinal degeneration.
Ophthalmology Times
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Modern Retina
SOL-1 results show intravitreal axitinib hydrogel delivered superior vision
maintenance and anatomic outcomes through 52 weeks.
Ophthalmology Times Europe
Charlie Zhang, MD, reflects on the rising incidence, diagnostic challenges and multidisciplinary management of immune checkpoint inhibitor–associated uveitis
Ophthalmology Times Europe
AI models predicting retinal function from OCT could transform geographic atrophy assessment in clinical care and trials
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
K. Thiran Jayasundera, MD, MS, FACS, on how patient interviews shaped a tool capturing functional and psychological burdens overlooked by visual acuity.
One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.
The meeting will include an Open Public Hearing.
Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial
Published: | Updated:
Remigromig met its BRUNELLO primary end point in DME, with higher PDR and vitreous hemorrhage rates than ranibizumab.
Reconstructing periocular defects in children requires planning for growth, not just repair.
EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still the most effective retina treatment.
Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.
Epithelial basement membrane dystrophy can affect premium IOL outcomes.
A checklist could help keep patients with geographic atrophy on track.
EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.
Advertisement
Topline data from the phase 2/3 study show that both dose levels of the subretinal gene therapy produced significant gains in low luminance visual acuity versus untreated control at 12 months.
Learn who benefits most from Encelto for MacTel type 2, its long-lasting CNTF implant results, and key safety counseling points.
Sessions at the 1-4 October Vienna congress address GA patient selection, AI-based functional prediction, imaging biomarkers, and surgical intervention.
NESTS survey reveals patients often normalize dry eye symptoms, delaying care despite major impacts on daily life.
The 26th EURETINA Congress convenes in Vienna, Austria, from October 1–4, headlined by a new World Retina networking initiative and a revamped Free Paper Forum stage.
Advertisement
Advertisement